Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2015 June;67(2) > Minerva Urologica e Nefrologica 2015 June;67(2):103-15

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

REVIEWS  


Minerva Urologica e Nefrologica 2015 June;67(2):103-15

language: English

Management of advanced bladder cancer in the era of targeted therapies

Soave A. 1, Engel O. 1, Von Amsberg G. 2, Becker A. 1, Dahlem R. 1, Shariat S. F. 3, Fisch M. 1, Rink M. 1

1 Department of Urology, University Medical Center Hamburg‑Eppendorf, Hamburg, Germany;
2 Department of Hematology and Oncology, University Medical Center Hamburg‑Eppendorf, Hamburg, Germany;
3 Department of Urology, Medical University of Vienna, Vienna, Austria


PDF  


Systemic chemotherapy is the standard treatment of advanced and metastatic urothelial carcinoma of the bladder (UCB). Unfortunately, systemic chemotherapy is ineffective in a significant number of patients, while side effects occur frequently. Detailed molecular-genetic investigations revealed a broad heterogeneity of underlying genomic mutations in UCB and led to the detection of cancer-specific therapeutic targets. These findings may allow a more tailored and individualized patient-based therapy, focusing on specific genomic variations, which may cause chemo-resistance in patients progressing or relapsing after standard chemotherapy. Targeted therapies hold the potential to be more effective in inhibiting cancer cell growth and progression, as well as to cause fewer side effects. While targeted therapies have been successfully established in the treatment of various malignancies including renal cell carcinoma, the clinical impact of these modern treatment strategies still remains unsettled for UCB. In this review, we comprehensively summarize the most current and relevant findings on targeted therapy in advanced and metastatic UCB, elucidating chances and limitations and discussing future perspectives.

top of page

Publication History

Cite this article as

Corresponding author e-mail

mrink@uke.de